Edgewise Therapeutics, Inc. — Director's Dealing 2021

Mar 26, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Edgewise Therapeutics, Inc. (EWTX)
CIK: 0001710072
Period of Report: 2021-03-25

Reporting Person: Wellington Biomedical Innovation Master Investors (Cayman) I L.P. (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series C Preferred Stock	$		Common Stock (681812)		Direct

Footnotes

F1: Each share of Series C Preferred Stock is convertible into one share of the Issuer's Common Stock at any time at the holder's election. Upon the closing of the Issuer's initial public offering, all such shares of Series C Preferred Stock will automatically convert into the number of shares of Common Stock of the Issuer shown in column 3. The Series C Preferred Stock has no expiration date.